Skip to main content

Pfizer's new trial vaccine for RSV is over 85% effective in older adults

Pfizer announced on Thursday that a vaccine designed to stop respiratory syncytial virus, or RSV, infections is over 85% effective in older adults.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.